Answers are grounded in this paper and cite their sources.
To understand the recent, evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), we retrospectively analyzed US claims data from MarketScan Commercial Claims and Encounters and Medicare databases and Symphony Health Solutions database for adult patients who initiated first-line DLBCL therapy from January 2017 through June 2023 (MarketScan) or May 2024 (Symphony). The MarketScan analysis included 3552 patients (median follow-up: 15 months). The Symphony analysis included 49,370 patients (median follow-up: 35 months). Results from this contemporary real-world analysis showed heterogeneity in DLBCL treatments administered, with a lack of standard of care in the third-line/fourth-line setting. In both analyses, most patients (>50% per line) received rituximab-based therapy as second-line or later-line therapy. These results highlight a need for new regimens that demonstrate clinical benefit and improve overall survival in patients with R/R DLBCL, while also being feasible and widely applicable in routine practice.
No takes yet. Share an insight, caveat, or question.
Phillips et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: